Cancers with a high prevalence of activating PIK3CA mutations include breast (>30%), endometrial (>30%), bladder (>20%), colorectal carcinoma (>17%), and head and neck squamous cell carcinoma (>15%) 8, 9, 10, 11. This evidence concerns the gene PIK3CA and colorectal carcinoma.